Key result
Early P2Y12 monotherapy vs DAPT after ACS PCI increases 30-day but not 1-year major events.
Answers are grounded in this paper and cite their sources.
Warrants caution with early P2Y12 monotherapy after ACS PCI; leaves open optimal transition timing.
CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
No takes yet. Share an insight, caveat, or question.
Manoj Kesarwani (2026) studied this question. P2Y12 inhibitor monotherapy compared to DAPT soon after PCI for ACS increased the composite risk of death or ischemic events at 30 days, but not at 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: